Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
Methods are provided for selecting proteins, in particular antibodies, against a wide variety of membrane proteins. In one aspect, a method is provided for eliciting monoclonal antibody in a non-human animal administered with a target membrane protein by using a fusion protein as an immunogen that contains a peptide fragment derived from the target membrane protein. The fusion protein can also be used as a ligand for screening a library of proteins for protein-ligand binding pairs in vitro by using mRNA, ribosome, phage, or cell display. The selected proteins can be used for therapeutics and diagnostics targeting the membrane proteins.
1 - 58 . (canceled)
59 . A method for selecting a protein that binds to a target membrane protein by ribosome display, comprising the step of
contact a library of ribosomes that display a library of tester proteins with a ligand that is a fusion protein between a peptide fragment of the target membrane protein and a chaperon protein that is heterologous to the target membrane protein and capable of stabilizing the peptide fragment;
isolating the ribosome that binds to the ligand; and
identifying the tester protein displayed by the selected ribosome.
60 . The method of claim 59 , wherein the library of the tester proteins is a library of antibodies selected from the group consisting of single chain antibodies, Fv fragments, Fab fragments, and fully assembled antibodies.
61 . The method of claim 59 , wherein the ligand is immobilized on a substrate.
62 . The method of claim 59 , wherein the peptide fragment has a length of 5-100 aa.
63 . The method of claim 59 , wherein the peptide fragment has a length of 10-80 aa.
64 . The method of claim 59 , wherein the peptide fragment has a length of 20-60 aa.
65 . The method of claim 59 , wherein the peptide fragment is an extracellular domain of the target membrane protein.
66 . The method of claim 59 , wherein the membrane protein is selected from the group consisting of receptors for growth factors, insulin receptor, MHC proteins, receptor for relaxin, CD3 receptor, T cell receptors, cytokine receptors, tyrosine-kinase-associated receptors and G-protein coupled receptors.
67 . The method of claim 66 , wherein receptors for growth factors are selected from the group consisting of receptors for vascular endothelial growth factor, epidermal growth factor, transforming growth factor, fibroblast growth factor, platelet derived growth factor, and insulin-like growth factor.
68 . The method of claim 66 , wherein the MHC protein is class I or class II MHC protein.
69 . The method of claim 66 , wherein the cytokine receptor is selected from the group consisting of interleukin-1 receptor, interleukin-2 receptor, interleukin-3 receptor, interleukin-4 receptor, interleukin-5 receptor, interleukin-6 receptor, interleukin-7 receptor, interleukin-8 receptor, interleukin-9 receptor, interleukin-10 receptor, interleukin-11 receptor, and interleukin-12 receptor.
70 . The method of claim 66 , wherein the tyrosine-kinase-associated receptors is selected from the group consisting of Src, Yes, Fgr, Flt, Lck, Lyn, Hck, and Blk.
71 . The method of claim 66 , wherein the G-protein coupled receptor is PSGR.
72 . The method of claim 66 , wherein the G-protein coupled receptor is a chemokine receptor.
73 . The method of claim 72 , wherein the chemokine receptor is selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CX3CR1, and XCR1.
74 . The method of claim 66 , wherein the G-protein coupled receptor is selected from the group consisting of beta1-adrenergic receptor, beta2-adrenergic receptor, parathyroid hormone receptor, EDG1, G10d, opioid receptors, neutensin recetpors, neuropeptide Y receptors, melatonin receptor, adrenocorticotrophin receptor, and leukotriene receptors.
75 . The method of claim 66 , wherein the G-protein coupled receptor is a 5-hydroxytryptamine or serotonin receptor.
76 . The method of claim 75 , wherein the serotonin receptor is selected from the group consisting of 5-TH1a, 5-TH1b, 5-TH1d, 5-TH1e, 5-TH1f, 5-TH2a, 5-TH2b, 5-TH2c, 5-TH3, 5-TH4, and 5-TH5 receptors.s
77 . The method of claim 66 , wherein the G-protein coupled receptor is selected from the group consisting of FSH receptor, LH/hCG recetpor, TSH receptor, formyl-methionyl peptide receptors, GABA receptors, endothelin receptors, sarafotoxin receptors, dopamin receptors, cannabinoid receptor, CGRP1 receptor, CGRP2 receptor, amylin receptor, calcitonin receptor, C5a receptor, bradykinin receptors, bombesin receptors, angiotensin receptors, adrenaline and noradrenaline receptors, acetylcholine receptors, platelet activating factor receptor, prostanoid receptors, somatostanin receptors, tachykinin Recetpors, thrombin receptor, GRF, PACAP, secretin, VIP and helodermin-preferring receptors, stresscopin receptor, urocortin receptor, corticotropin releasing hormone receptors, LGR4, LGR5, LGR6, LGR7 and LGR8.
78 . The method of claim 66 , wherein the G-protein coupled receptor is an orphan receptor selected from proteins designated as GPR1-GPR58 at GenBank.
79 . The method of claim 59 , wherein the chaperon protein is a DNA binding domain or an activation domain of a transcription factor.
80 . The method of claim 59 , wherein the chaperon protein is selected from the group consisting of Gal4 DNA binding domain, LexA binding domain, lambda cl DNA binding domain, cdc25, Sos, T18 bacterial protein, T25 bacterial protein, the alpha and omega fragments of beta-lactamase, glutathion-S-transferase (GST) and thioredoxin.
81 . The method of claim 59 , further comprising:
sequencing the DNA or the RNA of the selected ribosome to identify the DNA encoding the tester protein displayed thereon.
82 - 87 . (canceled)